Coronary Heart Disease Phlegm-blood Stasis-stagnation-deficiency Innovation Theory and Clinical Application Based on Complex System

Jie WANG; Guang CHEN

doi:10.13422/j.cnki.syfjx.20190750

您当前的位置：

首页 >

文章列表页 >

Coronary Heart Disease Phlegm-blood Stasis-stagnation-deficiency Innovation Theory and Clinical Application Based on Complex System

Monograph | 更新时间：2021-02-09

- Coronary Heart Disease Phlegm-blood Stasis-stagnation-deficiency Innovation Theory and Clinical Application Based on Complex System
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 1, Pages: 11-15(2019)
- 作者机构：
  
  1.中国中医科学院　广安门医院，北京　 100053
  2.北京中医药大学，北京　 100029
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20190750
  CLC： R22;R24;R541.4;R289
- Received：10 December 2018，
  
  Published Online：14 December 2018，
  
  Published：05 January 2019
- 稿件说明：
移动端阅览
Jie WANG, Guang CHEN. Coronary Heart Disease Phlegm-blood Stasis-stagnation-deficiency Innovation Theory and Clinical Application Based on Complex System[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(1): 11-15.
DOI：

Jie WANG, Guang CHEN. Coronary Heart Disease Phlegm-blood Stasis-stagnation-deficiency Innovation Theory and Clinical Application Based on Complex System[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(1): 11-15. DOI： 10.13422/j.cnki.syfjx.20190750.

摘要

冠心病的中医治疗历史上经历了温阳散寒、行气化痰、活血化瘀的变化趋势，其时空发展符合复杂系统理论。针对现代冠心病人群，创新性提出痰瘀滞虚理论，以指导临床提高疗效。理论方面，瘀滞是冠心病的疾病基本病机，贯穿冠心病病程的始终；痰这一要素随社会的发展已经并且仍在深刻地改变冠心病患者人群的证候特点；从冠心病虚的病理基础入手进行补养，可以延缓衰老过程，推迟疾病发生，延缓疾病进展，是中医区别于现代医学，发挥自身优势，解决冠心病难题的核心要旨。基于此，临证方面，冠心病的治疗应以活血化瘀通滞为疾病的基本治法，冠心2号方、血府逐瘀汤、栀子豉汤、当归拈痛汤可供冠心病不同阶段使用；通过药物的补养，调整身体的状态，从而预防冠心病发生以及延缓冠心病进展，如党参、黄芪、六味地黄丸、左归饮、右归饮均为补益佳品；香类药物既可化痰通脉止痛，又可宁心安神，消除冠心病患者紧张情绪，如沉香、檀香、麝香在冠心病治疗中均可得以妙用。

Abstract

There exits a trend of treatment for coronary heart disease(CHD) in terms of Chinese medicine(CM) in history

from warming Yang and dispelling cold

moving Qi and dissolving phlegm to invigorating blood and dissolving stasis

whose time-space development accords to the theory of complex system.Targeting the contemporary population of CHD

phlegm-blood stasis-stagnation-deficiency theory is proposed to direct clinical application to further improve effectiveness.From the perspective of theory

blood stasis-stagnation is the basic pathogenesis of CHD that runs through the whole period in the advance of CHD

while phlegm has been changing the feature of CM Zheng of CHD population with the development of the society

and nourishing the body according to the type of deficiency might delay the process of growing older

postpone the occur of disease and hinder the advance of disease

which genuinely differs from modern medicine to render the superiority of CM to work out the challenges of CHD.As for the clinical application

the treatment options could consider invigorating blood

dissolving stasis and removing stagnation as the basic method

such as CHD formula 2

Xuefu Zhuyutang

Zhizi Chitang and Danggui Niantongtang could be used in varied period of CHD.Moreover

boosting the body by herbal medicine could regulate the routine of body

then to prevent CHD and fear down the advance of CHD

for instance

Codonopsis Radix

Astragali Radix

Liuwei Dihuang pills

Zuoguiyin and Youguiyin.Furthermore

balmiest herbs could not only dissolve phlegm

unblock the meridian and relieve pain

but also calm the mind and eliminate the anxiety.For example

Aquilariae Lignum Resinatum

Santali Albi Lignum and Moschus could be used handily in the treatment of CHD.

关键词

Keywords

references

李柳骥．冠心病心绞痛古今中医文献整理与研究 [D]．北京：北京中医药大学， 2007 .

王阶，王永炎．复杂系统理论与中医方证研究 [J]．中国中医药信息杂志， 2001 ， 8 ( 9 ): 25 - 27 .

O'Gara P T , Kushner F G , Ascheim D D ,et al . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol , 2013 , 61 ( 4 ): e78 - e140 .

陆再英，钟南山．内科学 [M]. 7版．北京：人民卫生出版社， 2008 ： 267 .

Whelton P K , Carey R M , Aronow W S ,et al . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [J]. Circulation , 2018 , 138 ( 17 ): e484 - e594 .

International Diabetes Federation Guideline Development Group . Global guideline for type 2 diabetes [J]. Diabetes Res Clin Pract , 2014 , 104 ( 1 ): 1 - 52 .

Robinson J G , Stone N J. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk:a new paradigm supported by more evidence [J]. Eur Heart J , 2015 , 36 ( 31 ): 2110 - 2118 .

Fouquerel E , Lormand J , Bose A ,et al . Oxidative guanine base damage regulates human telomerase activity [J]. Nat Struct Mol Biol , 2016 , 23 ( 12 ): 1092 - 1100 .

Kubben N , ZHANG W , WANG L ,et al . Repression of the antioxidant NRF2 pathway in premature aging [J]. Cell , 2016 , 165 ( 6 ): 1361 - 1374 .

中华中医药学会心血管病分会．冠心病稳定型心绞痛中医诊疗专家共识 [J]．中医杂志， 2018 ， 59 ( 5 ): 447 - 450 .

PAN C , LOU L , HUO Y ,et al . Salvianolic acid B and tanshinone Ⅱ A attenuate myocardial ischemia injury in mice by NO production through multiple pathways [J]. Ther Adv Cardiovasc Dis , 2011 , 5 ( 2 ): 99 - 111 .

XU W , YANG J , WU L M. Cardioprotective effects of tanshinone Ⅱ A on myocardial ischemia injury in rats [J]. Pharmazie , 2009 , 64 ( 5 ): 332 - 336 .

Maione F , Cantone V , Chini M G ,et al . Molecular mechanism of tanshinone Ⅱ A and cryptotanshinone in platelet anti-aggregating effects:an integrated study of pharmacology and computational analysis [J]. Fitoterapia , 2015 , 100 : 174 - 178 .

ZHOU Z Y , HUANG B , LI S ,et al . Sodium tanshinone Ⅱ A sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish [J]. Toxicol Appl Pharmacol , 2018 , 350 : 32 - 42 .

ZHAO D , TONG L , ZHANG L ,et al . Tanshinone Ⅱ A stabilizes vulnerable plaques by suppressing RAGE signaling and NF- κ B activation in apolipoprotein-E-deficient mice [J]. Mol Med Rep , 2016 , 14 ( 6 ): 4983 - 4990 .

HU H , ZHAI C , QIAN G ,et al . Protective effects of tanshinone Ⅱ A on myocardial ischemia reperfusion injury by reducing oxidative stress,HMGB1 expression, and inflammatory reaction [J]. Pharm Biol , 2015 , 53 ( 12 ): 1752 - 1758 .

魏毅，张贵平．白芍总苷对血小板功能的影响 [J]．医学理论与实践， 2004 ， 17 ( 8 ): 871 - 872 .

LIU C , WANG J , YANG J. Study on activating blood and eliminating stasis of total paeony glycoside(TPG) [J]. J Chin Med Mater , 2000 , 23 ( 9 ): 557 - 560 .

LONG J , GAO M , KONG Y ,et al . Cardioprotective effect of total paeony glycosides against isoprenaline-induced myocardial ischemia in rats [J]. Phytomedicine , 2012 , 19 ( 8/9 ): 672 - 676 .

LI J , CHEN C X , SHEN Y H. Effects of total glucosides from paeony( Paeonia lactiflora Pall) roots on experimental atherosclerosis in rats [J]. J Ethnopharmacol , 2011 , 135 ( 2 ): 469 - 475 .

Kim E Y , Kim J H , Rhyu M R. Endothelium-independent vasorelaxation by Ligusticum wallichii in isolated rat aorta:comparison of a butanolic fraction and tetramethylpyrazine,the main active component of Ligusticum wallichii [J]. Biol Pharm Bull , 2010 , 33 ( 8 ): 1360 - 1363 .

Kim B , Kim J , Kim A ,et al . Ligusticum wallichi -induced vasorelaxation mediated by mitogen-activated protein kinase in rat aortic smooth muscle [J]. J Ethnopharmacol , 2004 , 90 ( 2/3 ): 397 - 401 .

PANG P K , SHAN J J , Chiu K W. Tetramethylpyrazine,a calcium antagonist [J]. Planta Med , 1996 , 62 ( 5 ): 431 - 435 .

Kim E Y , Rhyu M R. Synergistic vasorelaxant and antihypertensive effects of Ligusticum wallichii ，and Angelica gigas [J]. J Ethnopharmacol , 2010 , 130 ( 3 ): 545 - 551 .

汪昂．医方集解 [M]．北京：人民卫生出版社， 2006 ： 246 .

冯彬彬，张建海．党参不同配伍研究进展 [J]．中国实验方剂学杂志， 2016 ， 22 ( 19 ): 194 - 198 .

靳如娜，齐晓甜，孙蓉，等．经典名方当归补血汤的药效物质基础和质量控制研究进展 [J]．中国实验方剂学杂志， 2018 ， doi: 10.13422/j.cnki.syfjx.20190648 http://doi.org/10.13422/j.cnki.syfjx.20190648 .

李时珍．本草纲目 [M]．北京：华夏出版社， 2002 ： 1301,1306,1877 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Application and Mechanism of Sanrentang Based on Treating Different Diseases with Same Therapy： A Review

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Establishment and Evaluation of Rat Model of Acute Myocardial Infarction in Coronary Heart Disease with Qi and Yin Deficiency Syndrome Based on Sleep Deprivation Combined with Coronary Artery Ligation

Clinical Research on Guizhi Fulingwan in Treatment of Ovarian Cancer： A Review

Treatment of Edema with Zhulingtang： A Review

Related Author

DOU Xin

PAN Haidi

HE Changhui

WEN Xiaoqing

MEI Xiao

MA Yuanxin

DENG Hualiang

WANG Wei

Related Institution

The First Clinical Medical College，Shandong University of Traditional Chinese Medicine（TCM）

College of TCM，Shandong University of TCM

The Affiliated Hospital of Shandong University of TCM

School of Clinical Medicine，Beijing University of Chinese Medicine

Beijing Key Laboratory of Chinese Materia Pharmacology，National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases，Institute of Basic Medical Sciences， Xiyuan Hospital，China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰